FDA Authorizes Marketing of 3 Juul Products
The authorized products are part of the Juul2 e-cigarette system and include a tobacco-flavored pod, a menthol-flavored pod and the Juul2 device.
Aug 31, 2026 | 1 min read
The U.S. Food and Drug Administration (FDA) last week authorized the marketing of three new e-cigarette products through the premarket tobacco product application (PMTA) pathway. The authorized products are part of the Juul2 e-cigarette system made by Juul Labs Inc. and include a tobacco-flavored pod, a menthol-flavored pod and the Juul2 device.
The FDA said its review found that a substantial proportion of adults who smoke completely switched away from combustible cigarettes to the authorized Juul2 products, with the menthol-flavored pod having a higher rate of complete switching compared to the tobacco-flavored pod. Specifically, 19.9% to 34.6% of those using the tobacco-flavored pod and 28.4% to 49.3% of those using the menthol-flavored pod stopped smoking cigarettes entirely at six weeks according to its research.
To date, the FDA has authorized 48 e-cigarette products.
In July 2025, the FDA authorized several Juul e-cigarette products, including tobacco and menthol-flavored pods in 3% and 5% nicotine concentrations. The tobacco and menthol-flavored e-cigarette pods authorized today are 18 mg/mL, which is the equivalent of 1.5% to 1.6% nicotine concentration.
